VRDN · Viridian Therapeutics, Inc.

Viridian Therapeutics disclosed positive topline data from the REVEAL-2 phase 3 trial of elegrobart, a subcutaneous anti-IGF-1R antibody, in patients with chronic thyroid eye disease. The trial met its primary endpoint with highly statistically significant results: 50% proptosis responder rate for Q4W dosing and 54% for Q8W dosing at week 24, compared to 15% on placebo. This builds on prior successes with veligrotug in both active and chronic TED, where THRIVE and THRIVE-2 trials met primary and secondary endpoints, demonstrating rapid onset and durability of response. Veligrotug's BLA is under FDA Priority Review with Breakthrough Therapy Designation and a PDUFA date of June 30, 2026. For elegrobart, BLA submission is anticipated in Q1 2027. The company's pipeline extends to anti-TSHR IND in Q4 2026 and FcRn inhibitors, positioning Viridian for leadership in TED and autoimmune expansion. With $762M in cash as of March 31, 2026, plus potential $75M DRI milestone on veligrotug approval and future revenues, operations are funded through profitability if both assets are approved. This advances Viridian toward commercial launches in TED, a market affecting ~190K US patients with moderate-to-severe disease.